


1635
[Signature]



AMENDMENT TRANSMITTAL LETTER

Docket No.
27656/37821

Application No.
10/018,437-Conf. #4498

Filing Date
June 3, 2002

Examiner
T. C. Gibbs

Art Unit
1635

Applicant(s): Uwe Zangemeister-Wittke et al.

Invention: OLINGONUCLEOTIDE DERIVATIVES DIRECTED AGAINST HUMAN BCL-XL AND HUMAN BCL-2 MRNA

TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	17	- 26 =		x	
Independent Claims	2	- 3 =		x	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Other fee (please specify):					
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					0.00

☒ Large Entity

☐ Small Entity

☒ No additional fee is required for this amendment.

☐ Please charge Deposit Account No. _____ in the amount of \$ _____.
A duplicate copy of this sheet is enclosed.

☐ A check in the amount of \$ _____ to cover the filing fee is enclosed.

☐ Payment by credit card. Form PTO-2038 is attached.

☒ The Director is hereby authorized to charge and credit Deposit Account No. 13-2855 as described below. A duplicate copy of this sheet is enclosed.

☒ Credit any overpayment.

☒ Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.

[Signature]
Jeffrey S. Sharp
Attorney Reg. No.: 31,879

Dated: December 30, 2004

MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 30, 2004

Signature: *[Signature]* (Jeffrey S. Sharp)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date shown below.

Dated: December 30, 2004

Signature: 

Jeffrey S. Sharp

Docket No.: 27656/37821
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

ZANGEMEISTER-WITTKE et al.

Application No.: 10/018,437

Filed: June 3, 2002

For: OLIGONUCLEOTIDE DERIVATIVES
DIRECTED AGAINST HUMAN BCL-XL
AND HUMAN BCL-2 MRNA



Group Art Unit: 16352

Examiner: Terra C. Gibbs

**RESPONSE TO RESTRICTION REQUIREMENT
AND AMENDMENT UNDER 37 C.F.R. §1.111**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

This is in response to the Office Action dated November 30, 2004 in which claims 1-26 were subjected to a five-way restriction requirement. In response to the request, Applicants elect Group II (claim 2). Applicants also amend claims 3, 4, 7, 8 and 26 such that each of claims 3-18 now depend from elected claim 2 and specify below further restrictions as they were applied by the Examiner against Group I.

INTRODUCTORY COMMENTS

Prior to examination on the merits, please amend the above-identified U.S. patent application as follows:

A Current Listing of the Claims begins on Page 2 of this paper.

Remarks begin on Page 8 of this paper.